Emerging Trends to Drive Incretin-Based Drugs Market Growth at 7.2% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Incretin-Based Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of incretin-based drugs has shown vigorous growth in recent times and is expected to escalate from $25.89 billion in 2024 to $27.83 billion in 2025 with a compound annual growth rate (CAGR) of 7.5%. This considerable expansion during the historic period can be credited to factors such as the increasing incidence of type 2 diabetes worldwide, the development and introduction of GLP-1 receptor agonists like exenatide and liraglutide, high investments in research and development, favorable approval policies for DPP-4 and GLP-1 drugs, a noteworthy shift from insulin and sulfonylureas to contemporarily introduced drug classes, and the introduction of once-weekly injectable drugs.

How Will the Incretin-Based Drugs Market Size Evolve and Grow by 2029?
In the coming years, the market size for incretin-based drugs is predicted to experience substantial expansion, escalating to a predicted total of $36.7 billion in 2029, indicative of a compound annual growth rate (CAGR) of 7.2%. Several factors will fuel this surge during the forecast period, including the rising popularity of fixed-dose combination treatments, an increased emphasis on weight management and obesity-related diabetes, the expansion of personalized medicine and associated diagnostic tools, soaring demand for less invasive drug delivery methods, and an aging population exhibiting a greater number of co-existing medical conditions. The forecast period will also see notable trends, such as the adoption of incretin drugs into obesity treatment plans, the emergence of dual and triple agonists elevating metabolic outcomes, the incorporation of digital health into incretin treatments for tailored monitoring, the preference for combination treatments over single drug therapy for advanced diabetes management, and a shift towards long-lasting weekly injections to lessen the frequency of dosing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

What Drivers Are Propelling the Growth of Incretin-Based Drugs Market Forward?
The incretin-based drugs market is anticipated to grow due to the increasing incidence of Type 2 diabetes mellitus. This long-term metabolic disorder is typified by insulin resistance and defective insulin secretion, leading to high blood glucose levels. A bad diet and lack of physical activity are common root causes of Type 2 diabetes, as they result in insulin resistance, which consequently impedes the body's ability to control blood sugar levels. Incretin-based drugs can enhance the management of type 2 diabetes by stimulating insulin secretion post-consumption of food and decreasing glucagon production, thereby helping to lower blood glucose levels. These drugs also slow down gastric emptying and suppress hunger, assisting in blood sugar regulation and weight management. As an example, the National Health Service, a government department in the UK, reported in June 2024 that approximately 549,000 additional individuals in England were at risk of developing Type 2 diabetes in 2023. This pushes the overall count of people with prediabetes to more than 3.6 million, marking a nearly 20% rise from 2022. Thus, the escalating prevalence of Type 2 diabetes mellitus is fueling the expansion of the incretin-based drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Emerging Trends Are Transforming the Incretin-Based Drugs Market in 2025?
Prominent entities in the incretin-based drugs sector are concentrating on the creation of a generic version of drugs, aiming to deliver more efficient and patient-centered treatment approaches for type 2 diabetes. A generic drug is a medication that has identical active components, power, dosage manner, and administration route as a branded drug, but it's promoted under its chemical name without brand labels. For example, Hikma Pharmaceuticals PLC, a pharmaceutical company located in the UK, inaugurated the inaugural generic variant of Victoza (liraglutide) injection, 6 mg/mL, in the US in December 2024. It got the green light from the Food and Drug Administration (FDA) and is recommended as a complement to diet and physical exercise for better glycemic control in adult and pediatric patients aged ten years and above with type 2 diabetes, presenting a fresh, more pocket-friendly alternative amidst persistent scarcity of GLP-1 drugs.

What Are the Key Segments in the Incretin-Based Drugs Market?
The incretin-based drugs market covered in this report is segmented -

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:
1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Who Are the Key Players Shaping the Incretin-Based Drugs Market's Competitive Landscape?
Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

What Geographic Markets Are Powering Growth in the Incretin-Based Drugs Market?
North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24570

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.